本帖最后由 老马 于 2012-1-13 21:20 编辑 $ t) Q" M. L( G' U" ?: B
2 u1 f, ?# _+ [$ O, O7 q/ v
爱必妥和阿瓦斯丁的比较 H* p# [- r- I8 z ~: z" @. H
1 ^& N% [" G6 S( G. _
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
0 B ?4 w& P3 ?% g$ a
; t* E; R) T# W( o) M8 t; ^ f
5 [/ J& C( v/ B
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/% f2 d$ D7 I8 m7 ]% H2 o
==================================================& K% J" @4 i3 F: ]
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
: {1 {5 S: U8 c7 b6 YPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
" N* [/ y1 x! \/ l. y: E" v9 _Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
* I# D& F4 ~: {) @
|